Coronary Heart Disease, Lipid Profile, Medication Adherence, Self-efficacy, Transitional Care Model
Conditions
Brief summary
Patients with coronary heart disease (CHD) require long-term medication and lifestyle modification following percutaneous coronary intervention (PCI). However, they often face challenges such as poor medication adherence and inadequate self-management. This study aims to evaluate the effects of the transitional care model (TCM) on CHD patients after PCI, regarding medication adherence, self-efficacy, and lipid levels.
Detailed description
TCM improved medication adherence, self-efficacy, and lipid profiles in CHD patients after PCI, while enhancing overall patient satisfaction. Compared with routine nursing care, TCM yielded superior clinical benefits and is recommended for broader application in the post-PCI management of CHD patients.
Interventions
Patients assigned to the control group underwent routine nursing care based on the standardized medical treatment, including admission health education (PCI postoperative risk management and medication instructions), psychological counseling, dietary and exercise guidance, individualized rehabilitation planning, and discharge instructions. After discharge, patients attended routine outpatient follow-up visits, including laboratory testing of blood lipids, blood pressure, and blood glucose, without structured follow-up or WeChat-based education. Routine outpatient education and guidance were provided only.
Patients in the observation group received a 3-month TCM intervention delivered by specially trained nurses, in addition to routine nursing care.
Sponsors
Qing Wang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
47 Years to 58 Years
Healthy volunteers
No
Inclusion criteria
* patients clinically diagnosed with CHD according to established diagnostic criteria * patients who met the World Health Organization (WHO) indications for PCI * complete clinical data available
Exclusion criteria
* Patients with cognitive impairment * Patients with incomplete follow-up data. * Patients with comorbid malignancy * Patients with severe hepatic * Patients with renal insufficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Medication Adherence | Baseline (before discharge) and 3 months after discharge | Medication adherence will be assessed using the Medication Adherence Report Scale-5 (MARS-5). The scale consists of 5 items that evaluate nonadherent behaviors (e.g., forgetting to take medications, altering dosages). Each item is scored on a 5-point Likert scale (1="always" to 5="never"), with total scores ranging from 5 to 25. A higher total score indicates better medication adherence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-efficacy | Baseline (before discharge) and 3 months after discharge | Self-efficacy will be assessed using the General Self-Efficacy Scale (GSS). The GSS is a validated 16-item instrument, with each item scored from 0 to 4. Higher total scores reflect greater self-efficacy in managing health and adhering to treatment recommendations. |
| Lipid Profile | Baseline (before discharge) and 3 months after discharge. | Fasting serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) will be measured using an automated biochemical analyzer. All measurements will be performed in mmol/L. |
Countries
China
Outcome results
None listed